Design of KYSA-6, a Phase 2, Open-label, Multicenter Study of KYV-101, a Novel Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory Generalized Myasthenia Gravis (P7-11.034)

To evaluate the safety and efficacy of KYV-101 in patients with refractory generalized myasthenia gravis (MG).

Authors

James Chung (ORCID: https://orcid.org/0000-0002-9775-0208)
Aiden Haghikia (ORCID: https://orcid.org/0000-0001-9629-3298)
Ralf Gold (ORCID: https://orcid.org/0000-0002-7223-3052)
Dominic Borie (ORCID: https://orcid.org/0009-0008-3569-2576)

Institutions

Medizinische Hochschule Hannover (DE)
United Therapeutics (United States) (US)
Ruhr University Bochum (DE)

Publication Details

Journal: Neurology
Published: 2025-04-07
DOI: https://doi.org/10.1212/wnl.0000000000210631
Citations: 2
Primary Topic: CAR-T cell therapy research
Type: article
Field-Weighted Citation Impact: 2.09

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Design of KYSA-6, a Phase 2, Open-label, Multicenter Study of KYV-101, a Novel Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory Generalized Myasthenia Gravis (P7-11.034)

James Chung, Aiden Haghikia, Ralf Gold, Dominic Borie

Apr 7, 2025

2 citations

Neurology

CAR-T cell therapy research

2.09

article

Design of KYSA-6, a Phase 2, Open-label, Multicenter Study of KYV-101, a Novel Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory Generalized Myasthenia Gravis (P7-11.034)

James Chung, Aiden Haghikia, Ralf Gold, Dominic Borie

April 7, 2025article en

2 citations

Abstract

To evaluate the safety and efficacy of KYV-101 in patients with refractory generalized myasthenia gravis (MG).

NeurologyVol. 104(7_Supplement_1)

Medizinische Hochschule Hannover (DE), United Therapeutics (United States) (US), Ruhr University Bochum (DE)

Openalex Percentile: Top 13%

CAR-T cell therapy research

2.09

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Design of KYSA-6, a Phase 2, Open-label, Multicenter Study of KYV-101, a Novel Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory Generalized Myasthenia Gravis (P7-11.034) — James Chung, Aiden Haghikia, et al. · Neurology (2025) | TGRS Research Map | TGRS